STOCK TITAN

Evogene Reports Financial Results for the Third Quarter and First Nine Months of 2026, Highlighting Progress in Two Internal Development Programs

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Evogene (EVGN) reported a third-quarter net loss of $2.862 million for 2026, versus net income of $5.197 million a year earlier. Quarterly revenue fell to $141,000 from $312,000 after the Bayer collaboration ended in May 2026. For the first nine months, revenue fell to $822,000 from $3.189 million and the net loss widened to $10.525 million from $2.473 million. Cash, cash equivalents and short-term bank deposits totaled approximately $9.2 million at September 30, 2026.

Evogene is refining drug candidates for acute graft-versus-host disease ahead of studies to support an application for human testing. Its AgPlenus subsidiary identified compounds active against fungicide-resistant Septoria strains. In plant tissue tests, selected compounds reduced Septoria disease severity by up to 75% versus untreated controls.

Loading...
Loading translation...
11 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 15 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Drug candidate refinement is underway to select molecules and advance toward studies supporting an application for human testing.
  • Minor pointLoss per share from continuing operations narrowed to $0.17 from $0.27 in Q3 and to $0.75 from $0.84 over nine months.
  • Minor pointAcute graft-versus-host disease candidates showed activity at nanomolar concentrations, with preliminary results on drug handling and toxicity.
  • Minor pointAgPlenus compounds showed activity against fungicide-resistant Septoria strains and additional fungal pathogens.
  • Minor pointSeptoria disease severity fell by up to 75% versus untreated controls in plant tissue tests with selected compounds.
6 minor points
  • Minor pointCost of revenues fell to $92,000 from $157,000 in Q3 and to $428,000 from $1.810 million over nine months.
  • Minor pointNet research and development expense fell to $4.466 million from $4.635 million over nine months.
  • Minor pointSales and marketing expense fell to $200,000 from $358,000 in Q3 and to $908,000 from $1.061 million over nine months.
  • Minor pointNine-month general and administrative expense fell to $3.096 million from $3.154 million.
  • Minor pointQuarterly net financing income rose to $176,000 from $79,000.
  • Minor pointLavie Bio and Biomica operating expenses fell following the July 2025 ICL sale and the February 2026 Lishan licensing agreement.

Negative

  • Major pointNet results swung to a $2.862 million Q3 loss from $5.197 million in income; the nine-month loss widened to $10.525 million from $2.473 million.
  • Major pointRevenue fell to $141,000 from $312,000 in Q3 and to $822,000 from $3.189 million over nine months.
  • Major pointOutstanding ordinary shares rose to 18,052,405 at September 30, 2026, from 8,718,193 at December 31, 2025.
  • Moderate pointOperating loss widened to $2.982 million from $2.427 million in Q3 and to $8.369 million from $7.280 million over nine months.
  • Moderate pointCash, cash equivalents and short-term bank deposits fell to approximately $9.2 million at September 30, 2026, from $12.956 million at December 31, 2025.
  • Moderate pointQuarterly cash usage was approximately $2.4 million, including approximately $0.5 million for 18 months of directors’ and officers’ insurance. 7.9% of market cap
  • Moderate pointEquity attributable to Evogene shareholders fell to negative $3.728 million at September 30, 2026, from negative $82,000 at year-end 2025.
  • Moderate pointNine-month net financing results swung to $1.565 million in expense from $907,000 in income.
  • Moderate pointQuarterly net research and development expense rose to $1.528 million from $1.133 million.
  • Moderate pointWarrant transaction and non-recurring legal costs totaled approximately $0.3 million in Q3 and approximately $0.4 million over nine months. 6.3% of market cap
5 minor points
  • Minor pointDiscontinued operations swung to a $56,000 Q3 loss from $7.561 million in income and to a $548,000 nine-month loss from $3.983 million in income.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Filing-enabling studies for the drug program remain ahead, and the drug handling and toxicology findings are preliminary.
  • Minor pointGross profit fell to $49,000 from $155,000 in Q3 and to $394,000 from $1.379 million over nine months.
  • Minor pointBayer’s license and collaboration agreement ended in May 2026, which Evogene cited as the main reason for lower quarterly revenue.
  • Minor pointOther operating expenses were $191,000 in Q3 versus none a year earlier and $293,000 over nine months versus $191,000 in income.

News Explained

Evogene reported 18,052,405 ordinary shares outstanding at September 30, 2026, versus 8,718,193 at December 31, 2025; the higher share count reduces each existing holder’s percentage ownership, absent offsetting changes.

Key Figures

Cash, cash equivalents and short-term bank deposits: approximately $9.2 million Nine-month revenue: approximately $0.8 million vs. approximately $3.2 million Third-quarter revenue: approximately $0.1 million vs. approximately $0.3 million +3 more
Cash, cash equivalents and short-term bank deposits
approximately $9.2 million
As of September 30, 2026
Nine-month revenue
approximately $0.8 million vs. approximately $3.2 million
Nine months of 2026 vs. the same period of 2025
Third-quarter revenue
approximately $0.1 million vs. approximately $0.3 million
Q3 2026 vs. Q3 2025
Nine-month net loss
approximately $10.5 million vs. approximately $2.5 million
Nine months ended September 30, 2026 vs. 2025
Third-quarter net result
approximately $2.9 million net loss vs. $5.2 million net income
Q3 2026 vs. Q3 2025
Disease severity reduction
up to 75%
Selected fungicide compounds in plant tissue assays vs. untreated controls

Previous Earnings Reports

1 past event · Latest: May 20
Same Type 1 event
  1. May 20

    Q1 earnings report

    24h Move
    -3.2%

    Revenue declined and net loss increased year over year; shares fell 3.24%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

agvhd, adme, ind-enabling studies
3 terms
agvhd medical
"targeting acute graft-versus-host disease (aGVHD)"
Acute graft-versus-host disease (aGVHD) is an immune complication that can occur after an allogeneic hematopoietic stem cell or bone marrow transplant, when donor immune cells recognize the recipient’s tissues as foreign and attack them. It typically appears within the first 100 days after transplant and most often affects the skin, gastrointestinal tract (including stomach and intestines), and liver, producing rashes, diarrhea, abdominal pain, nausea, and abnormal liver tests. Severity is classified by clinical grading systems based on the extent and intensity of organ involvement, and management centers on suppressing or modulating the donor immune response. aGVHD is specific to transplants where donor immune cells are present and does not occur with autologous (self) transplants.
adme medical
"encouraging preliminary ADME and toxicology profiles"
ADME stands for Absorption, Distribution, Metabolism and Excretion — the four processes that determine how a drug enters the body, moves to target tissues, is chemically changed, and is removed. For investors, ADME profiles signal whether a drug is likely to be effective, safe and practical to dose; weak ADME can sink a program just like delivery problems can ruin a product launch, while strong ADME improves chances of regulatory approval and commercial success.
ind-enabling studies regulatory
"advancing the program toward IND-enabling studies"
Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company advances its internally developed drug discovery program targeting acute graft-versus-host disease (aGVHD) and AgPlenus' fungicide discovery programs targeting novel MoA against Septoria

REHOVOT, Israel, Nov. 19, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a computational chemistry company leveraging proprietary AI-driven technologies to design and develop novel small molecules for the pharmaceutical and agricultural industries, today reported its financial results for the third quarter and first nine months of 2026, and provided an update on its business activities.

Evogene Logo

Ofer Haviv, Evogene's President and CEO, stated: "During the third quarter, we continued to advance our strategy of leveraging our proprietary AI-driven discovery platform, ChemPass AI™, to develop innovative small-molecule-based products with significant commercial potential. Alongside our collaborative discovery activities, we are advancing two internal development programs that represent an important component of our strategy to build a pipeline of proprietary assets fully owned and managed by Evogene.

The first one is our internal drug discovery program targeting acute graft-versus-host disease (aGVHD), a serious medical condition associated with significant unmet medical need. Within just several months, Using ChemPass AI™, we generated a series of novel, small-molecule candidates, that demonstrated biological potency, at nanomolar concentrations, as well as encouraging preliminary ADME and toxicology profiles. We are now focused on further optimizing these molecules, identifying the most promising candidates, and advancing the program toward IND-enabling studies. (For more information, please see our PR from 28, October 2026)

The second program, conducted through our subsidiary AgPlenus, focuses on discovering fungicides with new modes of action targeting Septoria tritici blotch, a major wheat disease for which resistance to existing fungicides is a growing challenge. Using ChemPass AI for Ag™, AgPlenus identified compounds that showed promising activity against fungicide-resistant Septoria strains. Selected compounds also reduced disease severity by up to 75%, compared to untreated controls, in plant tissue assays and demonstrating activity against additional fungal pathogens, indicating broader fungicidal potential. (For more information, please see our PR from 17, November 2026)

The progresses achieved across these initiatives demonstrates the ability of ChemPass AI™ and ChemPass AI for Ag™ to translate computational discovery into experimentally validated molecules exhibiting promising biological activity. More importantly, these programs reflect our strategic focus on converting technological capabilities into differentiated, proprietary product candidates offering meaningful commercial potential, ultimately creating long-term value for Evogene and its shareholders. "

Financial Results and Analysis

Cash Position

As of September 30, 2026, Evogene held consolidated cash, cash equivalents and short-term bank deposits of approximately $9.2 million. Consolidated cash usage during the third quarter of 2026 was approximately $2.4 million, including a Directors' and Officers' insurance payment of approximately $0.5 million, covering an 18-month period.

Revenues

Revenues for the nine months of 2026 totaled approximately $0.8 million, compared to approximately $3.2 million in the same period of 2025, representing a decrease of approximately $2.4 million. The decrease is mainly attributable to lower revenue recognized by Casterra, which in the first half of 2025 included significant seed sales of approximately $2.0 million. Revenues for the third quarter of 2026 were approximately $0.1 million compared to approximately $0.3 million in the third quarter of 2025, mainly due to the conclusion of the license and collaboration agreement with Bayer in May 2026.

Research and Development Expenses

Research and development expenses, net of non-refundable grants, for the nine months of 2026 were approximately $4.5 million, compared to approximately $4.6 million in the corresponding period of 2025, representing a decrease of approximately $0.1 million. For the third quarter of 2026, R&D expenses were approximately $1.5 million, an increase from $1.1 million in the same period of 2025. The increase was mainly attributable to the recognition of a non-refundable grant of approximately $0.2 million and an adjustment to liabilities in respect of government grants of approximately $0.1 million, both of which reduced R&D expenses in the third quarter of 2025, as well as the impact of fluctuations in the USD/NIS exchange rate, between the periods.

Sales and Marketing Expenses

Sales and marketing expenses for the nine months of 2026 were approximately $0.9 million, compared to approximately $1.1 million in the corresponding period of 2025. Sales and marketing expenses for the third quarter of 2026 were approximately $0.2 million, compared to approximately $0.4 million in the third quarter of 2025, primarily due to lower sales and marketing expenses at Casterra and AgPlenus.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2026, decreased slightly to approximately $3.1 million, compared to approximately $3.2 million in the corresponding period of 2025. For the third quarter of 2026, general and administrative expenses were approximately $1.1 million, remaining relatively unchanged compared to the same period of 2025. The decrease in general and administrative expenses across Evogene and its subsidiaries was largely offset, mainly by transaction costs associated with the warrant inducement transaction and additional non-recurring legal expenses related to corporate governance and shareholders matters. These costs totaled approximately $0.4 million and $0.3 million during the nine-month and three-month periods ended September 30, 2026, respectively.

Financing Expenses (Income), Net

Financing expenses, net, for the nine months of 2026 were approximately $1.6 million, compared to financing income, net, of approximately $0.9 million in the corresponding period of 2025. This change was primarily related to the accounting treatment and revaluation of warrants, including warrants issued in the August 2024 financing and the February 2026 warrant inducement transaction. As part of the February 2026 warrant inducement transaction, the Company recorded financing expenses of approximately $3.8 million during the first nine months of 2026. In addition, the Company recorded financing income of approximately $2.3 million related to the revaluation of warrants liability as of September 30, 2026. For the third quarter of 2026, financing income, net, was approximately $176 thousand, compared to approximately $79 thousand in the corresponding period of 2025, with no material change between the periods.

Loss from Discontinued Operations

Loss from discontinued operations, net, for the nine months of 2026 was approximately $0.5 million, compared to an income from discontinued operations, net, of approximately $4.0 million in the corresponding period of 2025. For the third quarter of 2026, the loss from discontinued operations was approximately $0.06 million, compared to income of approximately $7.6 million in the third quarter of the previous year. These amounts primarily reflect the financial results of Lavie Bio's and Biomica's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, which are presented as a single-line item in the consolidated statements of profit and loss. Following the sale of the majority of Lavie Bio's assets, as well as Evogene's MicroBoost AI for Ag, to ICL in July 2025 and the licensing agreement with Lishan in February 2026, Lavie Bio's and Biomica's operating expense levels have decreased significantly. Biomica's operations were classified as discontinued operations beginning in the second quarter of 2026, and accordingly, the 2025 comparative figures have been reclassified to conform to the current period presentation. Lavie Bio's operations, as well as expenses related to the development and maintenance of MicroBoost AI for Ag, had already been classified as discontinued operations in 2025.

Net loss for the nine months ended September 30, 2026, was approximately $10.5 million, compared to approximately $2.5 million in the corresponding period of 2025. The $8.0 million increase in net loss was primarily attributable to lower revenues, higher financing expenses, and income recognized in connection with the ICL transaction during the corresponding period of 2025. For the third quarter of 2026, net loss was approximately $2.9 million, compared to net income of approximately $5.2 million in the same period of 2025. The change was primarily attributable to income recognized in connection with the ICL transaction during the third quarter of 2025, as discussed above.

About Evogene Ltd.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products. At the core of its technology is ChemPass AITM, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com. 

About AgPlenus Ltd. 

AgPlenus, a subsidiary of Evogene Ltd., is an AI-driven crop protection discovery company focused on developing effective and sustainable solutions to address the growing challenge of pesticide resistance. The company leverages ChemPass AI for Ag™, a technology platform licensed from Evogene, integrating predictive biology, artificial intelligence, and computational chemistry to discover novel crop-protection molecules. Through its target-based discovery approach, AgPlenus aims to improve discovery efficiency, reduce development risks, and advance differentiated crop-protection solutions with the potential to address unmet agricultural needs. 

For more information, please visit www.agplenus.com

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses, among other things: its advancing its existing pharmaceutical and agricultural division programs toward subsequent stages of development; its potential, future revenue generation as its pharmaceutical programs progress through development and toward commercialization; its potential establishment of additional collaborations with leading biotechnology and pharmaceutical companies; its advancement of its internal high-value programs, including its internal drug discovery program under which proprietary molecules have the potential to serve as candidates for future preclinical development; its  discovery program for new fungicides via AgPlenus; pursuit of strategic partnerships in agriculture; its continuing to strengthen its computational platform; and its ability to execute its strategy and create long-term shareholder value.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including: the aftermath of the recent wars between Israel and the United States, on the one hand, and Iran and its proxy  terrorist groups, Hamas, Hezbollah, and, intermittently, the Houthis in Yemen, on the other hand, (and any destabilizations in Israel, neighboring territories or the Middle East region resulting from those wars; Evogene's and its subsidiaries' reliance on third parties to conduct certain activities, such as field-trials and pre-clinical studies, which could cause significant delays in the conduct of those activities; the potential impact of a change of control of Evogene's board of directors due to the actions of dissident shareholders; as well as those additional risk factors identified in Evogene's reports filed with the applicable securities authority. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Evogene's actual results to differ from those reflected in its forward-looking statements, please see "Item 3.D. Risk Factors" in Evogene's Annual Report on Form 20-F for the year ended December 31, 2025, and its subsequent reports filed with or furnished to the U.S. Securities and Exchange Commission and Israeli Securities Authority. You should not place undue reliance on any forward-looking statements included in this press release. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions, except to the extent required by applicable law.

Investor Relations Contact:

ir@evogene.com
Tel: +972-8-9311901

 

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands




September 30,


December 31,



2026


2025



Unaudited



ASSETS





CURRENT ASSETS:





Cash and cash equivalents


$               8,571


$               12,956

Restricted cash


33


32

Short-term bank deposits


655


-

Trade receivables


232


317

Other receivables and prepaid expenses


1,181


1,565

Deferred expenses related to issuance of warrants


-


551

Inventories


65


210








10,737


15,631

LONG-TERM ASSETS:





Long-term deposits and other receivables


5


571

Investment accounted for using the equity method


-


43

Deferred expenses related to issuance of warrants


-


1,165

Right-of-use-assets


1,446


1,824

Property, plant and equipment, net


446


812








1,897


4,415






TOTAL ASSETS


$               12,634


$               20,046






LIABILITIES AND EQUITY










CURRENT LIABILITIES:





Trade payables


$                 593


$                639

Employees and payroll accruals


703


861

Lease liabilities


618


716

Liabilities in respect of government grants


142


56

Deferred revenues and other advances


21


17

Warrants and pre-funded warrants liability


496


706

Other payables


389


449








2,962


3,444

LONG-TERM LIABILITIES:





Lease liabilities


1,287


1,482

Liabilities in respect of government grants


3,082


3,073

Deferred revenues and other advances


60


72








4,429


4,627






TOTAL LIABILITIES


$             7,391


$             8,071

 

CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

U.S. dollars in thousands



SHAREHOLDERS' EQUITY:





Ordinary shares of NIS 0.2 par value:

Authorized − 30,000,000 ordinary shares; Issued and
outstanding – 18,052,405 ordinary shares on September
30, 2026 and 8,718,193 ordinary shares on December
31, 2025


1,103


488

Share premium and other capital reserves


288,212


281,986

Accumulated deficit


(293,043)


(282,556)






Equity attributable to equity holders of the Company


(3,728)


(82)






Non-controlling interests


8,971


12,057






TOTAL EQUITY


5,243


11,975






TOTAL LIABILITIES AND EQUITY


$             12,634


$             20,046

 

CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

U.S. dollars in thousands (except share and per share amounts)




Nine months ended

September 30,


Three months ended

September 30,


Year ended

 December 31,



2026


2025 (*)


2026


2025 (*)


2025 (*)



Unaudited


Audited












Revenues


$       822


$       3,189


$      141


$      312


$      3,503












Cost of revenues:











   Inventory impairment


-


-


-


-


2,180

   Other cost of revenues


428


1,810


92


157


1,914

Total Cost of Revenues


428


1,810


92


157


4,094












Gross profit


394


1,379


49


155


(591)

Operating expenses:






















Research and development, net


4,466


4,635


1,528


1,133


6,262

Sales and marketing


908


1,061


200


358


1,359

General and administrative


3,096


3,154


1,112


1,091


4,021

Other expenses (income)


293


(191)


191


-


(205)












Total operating expenses, net


8,763


8,659


3,031


2,582


11,437












Operating loss


(8,369)


(7,280)


(2,982)


(2,427)


(12,028)












Financing income


2,559


2,352


255


513


2,618

Financing expenses


(4,124)


(1,445)


(79)


(434)


(1,841)












Financing income (expenses), net


(1,565)


907


176


79


777












Share of loss from equity accounted investment


((43


(82)


-


(16)


(39)












Loss before taxes on income


(9,977)


(6,455)


(2,806)


(2,364)


(11,290)

Taxes on income (tax benefit)


-


1


-


-


1

Loss from continuing operations


(9,977)


(6,456)


(2,806)


(2,364)


(11,291)

Income (loss) from discontinued operations, net


(548)


3,983


(56)


7,561


3,464












Net income (loss)


$     (10,525)


$     (2,473)


$    (2,862)


$   5,197


$   (7,827)












Attributable to:











Equity holders of the Company


$     (10,487)


$     (3,176)


$   (2,849)


$   3,874


(8,485)

Non-controlling interests


(38)


703


(13)


1,323


658














$         (10,525)


$     (2,473)


$   (2,862)


$   5,197


$  (7,827)

Basic and diluted loss per share from
continuing operations, attributable to equity
holders of the Company


$       (0.75)


$       (0.84)


$     (0.17)


$     (0.27)


$      (1.41)

Basic and diluted loss per share from
discontinued operations, attributable to
equity holders of the Company


$       (0.04)


$          0.42


$     (0.00)


$        0.71


$      0.33












Weighted average number of shares used in
computing basic and diluted loss per share


13,245,869


7,588,486


16,894,446


8,716,424


7,874,039


     (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
      discontinued operations.

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands



 

Nine months ended

September 30,


Three months ended

September 30,


 


Year ended

December 31,



2026


2025 (*)


2026


2025 (*)


 

2025 (*)



Unaudited


Audited

    Cash flows from operating activities






















Loss from continuing operations


$    (9,977)


$    (6,456)


$    (2,806)


$    (2,364)


$  (11,291)












Adjustments to reconcile loss to net cash used in operating activities:


















Adjustments to the profit or loss items:






















Depreciation of property, plant and equipment and right-of-use-assets


501


748


167


241


971

Impairment of Property, Plant and Equipment


116


-


-


-


-

Inventory impairment


-


-


-


-


2,180

Share-based compensation


80)


570


(13)


125


728

Remeasurement of Convertible SAFE


-


(371)


-


(26)


(371)

Net financing expenses (income)


(73)


21


(81)


(135)


(28)

Loss (gain) from sale of property, plant and equipment


(17)


(192)


(3)


2


(205)

Revaluation of government grants


27


24


18


24


40

Amortization of deferred expenses related to issuance of warrants


1,716


989


-


333


1,323

Remeasurement of pre-funded warrants and warrants


(2,271)


(1,664)


(163)


(346)


(1,781)

Expenses related to warrants inducement transaction


2,095


-


-


-


-

Share of loss of an associate


43


82


-


15


39

Allowance for doubtful accounts


78


-


78


-


-

Investment in sub-lease


194


-


194


-


-

Taxes on income (tax benefit)


-


1


-


-


(6)














2,489


208


197


233


2,890

Changes in asset and liability items:

 











Decrease in trade receivables


7


667


74


730


665

Decrease (increase) in other receivables and prepaid expenses


(114)


870


(388)


(417)


958

Decrease (increase) in inventories


145


(740)


28


(139)


(1,019)

Increase (decrease) in trade payables


62


(195)


187


(31)


(40)

Decrease in employees and payroll accruals


(143)


(335)


(204)


(226)


(494)

Increase (decrease) in other payables


16


(343)


117


(45)


(344)

Decrease in deferred revenues and other advances


(8)


(356)


(5)


(5)


(361)














(35)


(432)


(191)


(133)


(635)

     (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
      discontinued operations.

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands




Nine months ended

September 30,


Three months ended

September 30,


Year ended

December 31,



2026


2025 (*)


2026


2025 (*)


2025 (*)



Unaudited


Audited

Cash received (paid) during the period for:






















Interest received


246


221


46


45


338

Interest paid


(104)


(221)


(20)


(70)


(256)

Taxes paid


(5)


(11)


-


-


(11)












Net cash used in continuing operating activities


(7,386)


(6,691)


(2,774)


(2,289)


(8,965)












Net cash provided by (used in) discontinued operations activities


(287)


(4,125)


13


(1,044)


(4,537)












Net cash used in operating activities


$   (7,673)


$   (10,816)


$    (2,761)


$    (3,333)


$   (13,502)












Cash flows from investing activities:

































Purchase of property, plant and equipment


$         (13(


(129)


(2)


(7)


$      (199)

Proceeds from sale of property, plant and equipment


115


10


3


10


78

Proceeds from finance sub-lease asset


17


29


-


12


52

Investment in bank deposits, net


(655)


(3,700)


(655)


(2,699)


(1)












Net cash provided by (used in) continuing investing activities


(536)


(3,790)


(654)


(2,684)


(70)












Net cash provided by (used in) discontinued investing activities


483


11,265


483


13,593


17,808












Net cash provided by (used in) investing activities


$           53) (


$    7,475


$   (171)


$   10,909


$     17,738












     (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
     discontinued operations.

 

CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

U.S. dollars in thousands




Nine months ended

September 30,


Three months ended

September 30,


Year ended

December 31,



2026


2025 (*)


2026


2025 (*)


2025 (*)




Unaudited


Audited


Cash flows from financing activities:
























Proceeds from issuance of ordinary shares,
net of issuance expenses


 

3,155


4,283


2,350


-


4,283


Proceeds from issuance of ordinary shares
in warrant inducement transaction, net of
issuance expenses


 

 

3,206


-


-


-


-


Repayment of lease liability


(334)


(315)


(121)


(87)


(423)


Dividend paid by subsidiary


(2,672)


-


-


-


-


Repayment of convertible SAFE


-


(10,000)


-


(10,000)


(10,000)


Proceeds from government grants


101


-


-


-


-


Repayment of government grants


(34)


(122)


(14)


-


(244)














Net cash provided by (used in) continuing
financing activities


3,422


(6,154)


2,215


(10,087)


(6,384)














Net cash used in discontinued financing
activities


(80)


(192)


(30)


(249)


(218)














Net cash provided by (used in) financing
activities


$       3,342


$    (6,346)


$   2,185


$   (10,336)


$     (6,602)














Exchange rate differences - cash and cash
equivalent balances


(1)


12


2


(13)


21














Decrease in cash and cash equivalents


(4,385)


(9,675)


(745)


(2,773)


(2,345)














Cash and cash equivalents, beginning of the
period


12,956


15,301


9,316


8,329


15,301


Cash and cash equivalents presented in
assets held for sale


-


-


-


70


-














Cash and cash equivalents, end of the period


$    8,571


$    5,626


$    8,571


$    5,626


$    12,956














Significant non-cash activities












Acquisition of property, plant and
equipment


$            -


$            2


$        -


$           -


$         2


Right-of-use asset recognized with
corresponding lease liability


$          33


$         207


$-


$      -


$      207


Exercise of pre-funded warrants


$         -


$         389


$          -


$          -


$      389


Derecognition of property, plant and
equipment under a finance lease


$          -


$           13


$          -


$                -


13         $



     (*) Reclassified to conform to the current period presentation, following the classification of certain operations as
      discontinued operations.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-reports-financial-results-for-the-third-quarter-and-first-nine-months-of-2026-highlighting-progress-in-two-internal-development-programs-302945292.html

SOURCE Evogene

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What drove Evogene’s swing to a net loss in Q3 2026?

Evogene attributed the swing primarily to income from the ICL transaction in Q3 2025. The transaction involved the July 2025 sale of most of Lavie Bio’s assets and Evogene’s MicroBoost AI for Ag to ICL.

Why did Evogene’s revenue fall in the first nine months of 2026?

Evogene attributed the decline mainly to lower revenue at Casterra. Casterra’s revenue in the first half of 2025 included approximately $2.0 million in seed sales.

What drove Evogene’s net financing expense in the first nine months of 2026?

Evogene mainly attributed the change to warrant accounting and revaluation. The February 2026 warrant inducement transaction generated approximately $3.8 million in financing expense over the first nine months, while the warrant liability revaluation as of September 30, 2026 generated approximately $2.3 million in financing income.

Keep reading